[HTML][HTML] AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa

AJ Smith, FC Schlichtenbrede, M Tschernutter… - Molecular therapy, 2003 - cell.com
AJ Smith, FC Schlichtenbrede, M Tschernutter, JW Bainbridge, AJ Thrasher, RR Ali
Molecular therapy, 2003cell.com
Abstract In the Royal College of Surgeons (RCS) rat, the retinal pigment epithelium (RPE)
cannot phagocytose the outer segment discs that are continually shed from photoreceptors.
The resulting accumulation of debris in the subretinal space leads to a progressive loss of
photoreceptors. The defect results from a mutation in the Mertk gene, which is normally
expressed in the RPE. Mertk is a receptor tyrosine kinase, involved in the binding of
photoreceptor debris. Mutations in MERTK have also been described in patients with retinitis …
Abstract
In the Royal College of Surgeons (RCS) rat, the retinal pigment epithelium (RPE) cannot phagocytose the outer segment discs that are continually shed from photoreceptors. The resulting accumulation of debris in the subretinal space leads to a progressive loss of photoreceptors. The defect results from a mutation in the Mertk gene, which is normally expressed in the RPE. Mertk is a receptor tyrosine kinase, involved in the binding of photoreceptor debris. Mutations in MERTK have also been described in patients with retinitis pigmentosa (RP). Here we demonstrate that subretinal injection of recombinant adeno-associated virus (AAV) expressing the murine Mertk gene can significantly prolong photoreceptor cell survival in the RCS rat. Electroretinographic analysis of treated eyes showed that functional photoreceptors were still present at 9 weeks, when there is virtually no activity in untreated control eyes. Histological analysis of treated eyes revealed a decrease in the amount of debris in the subretinal space, suggesting that RPE function was restored. Moreover, 9 weeks after treatment the number of photoreceptors was 2.5-fold higher in treated than in control eyes. This study provides strong support for the development of AAV-mediated gene therapy for RP caused by mutations in the MERTK gene.
cell.com